Cited by 573Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Open access

Kelly, Karen, Chansky, Kari, Gaspar, Laurie E., Albain, Kathy S., Jett, James, Ung, Yee C., Lau, Derick H.M., Crowley, John J., Gandara, David R.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.4824

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients with advanced non-small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal agent to evaluate in a maintenance setting in stage III disease. PATIENTS AND METHODS: Untreated patients with stage III NSCLC, a performance score of 0 to 1, and adequate organ function were eligible. All patients received cisplatin 50 mg/m(2) on days 1 and 8 plus etoposide 50 mg/m(2) on days 1 to 5, every 28 days for two cycles with concurrent thoracic radiation (1.8- to 2-Gy fractions per day; total dose, 61 Gy) followed by three cycles of docetaxel 75 mg/m(2). Patients whose disease did not progress were randomly assigned to gefitinib 250 mg/d or placebo until disease progression, intolerable toxicity, or the end of 5 years. The planned sample size was 672 patients to confer power of 0.89 to detect a 33% increase over the expected median survival time of 21 months (one-sided P = .025, log-rank test). Random assignment was stratified by stage, histology, and measurable versus nonmeasurable disease. RESULTS: Enrollment began in July 2001. An unplanned interim analysis conducted in April 2005 rejected the alternative hypothesis of improved survival at the P = .0015 level for 243 randomly assigned patients. The study closed, and preliminary results were reported. Now, with a median follow-up time of 27 months, median survival time was 23 months for gefitinib (n = 118) and 35 months for placebo (n = 125; two-sided P = .013). The toxic death rate was 2% with gefitinib compared with 0% for placebo. CONCLUSION: In this unselected population, gefitinib did not improve survival. Decreased survival was a result of tumor progression and not gefitinib toxicity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.4824

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490

Flagged first, then by citations

Show all 31 references

Sorted by citations

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,301
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
Auperin, A., Pechoux, C. L., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J. S. A., Clamon, G. H., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,882
Non–Small Cell Lung Cancer
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 737
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716
CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma
Coroller, T. P., Grossmann, P., Hou, Y., Rios Velazquez, E., Leijenaar, R. T. H., Hermann, G., Lambin, P., Haibe-Kains, B., Mak, R. H., & Aerts, H. J. W. L. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.015 · Cited by 695
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Butts, C. A., Socinski, M. A., Mitchell, P. L. R., Thatcher, N., Havel, L., Krzakowski, M. J., Nawrocki, S., Ciuleanu, T., Bosquée, L., Trigo, J. M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 539
Guidelines on the radical management of patients with lung cancer
Lim, E. K. S., Baldwin, D., Beckles, M. A., Duffy, J. P., Entwisle, J. J., Finn, C. F., Kerr, K. M., Macfie, A., McGuigan, J., Padley, S. P. G., et al. (2010) · Thorax · doi:10.1136/thx.2010.145938 · Cited by 546
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Zhong, W., Wang, Q., Mao, W., Xu, L., Wu, L., Shen, Y., Liu, Y., Chen, C., Cheng, Y., Xu, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30729-5 · Cited by 537
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vansteenkiste, J., Ruysscher, D. D., Eberhardt, W., Lim, E. K. S., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 486
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
Kelly, K. L., Altorki, N. K., Eberhardt, W., O'Brien, M. E. R., Spigel, D. R., Crinò, L., Tsai, C., Kim, J.-H., Cho, E. K., Hoffman, P. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.8918 · Cited by 485
Self-citation
Lung cancer: New biological insights and recent therapeutic advances
Ramalingam, S. S., Owonikoko, T. K., & Khuri, F. R. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20102 · Cited by 472
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
Senan, S., Brade, A. M., Wang, L.-H., Vansteenkiste, J., Dakhil, S. R., Biesma, B., Aguillo, M. M., Aerts, J. G. J. V., Govindan, R., Rubio‐Viqueira, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8824 · Cited by 434
Self-citation
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
Eberhardt, W., Ruysscher, D. D., Weder, W., Pechoux, C. L., Leyn, P. D., Hoffmann, H., Westeel, V., Stahel, R. A., Felip, E., Peters, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv187 · Cited by 400
European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer
Ruysscher, D. D., Finn, C. F., Nestle, U., Hurkmans, C., Pechoux, C. L., Price, A., & Senan, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3271 · Cited by 364
Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
Goss, G. D., O’Callaghan, C. J., Lorimer, I. A. J., Tsao, M., Masters, G. A., Jett, J. R., Edelman, M. J., Lilenbaum, R., Choy, H., Khuri, F. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1816 · Cited by 357
Self-citation
Refining the treatment of NSCLC according to histological and molecular subtypes
Thomas, A., Liu, S. V., Subramaniam, D. S., & Giaccone, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.90 · Cited by 323
Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group
Machtay, M. X., Bae, K., Movsas, B., Paulus, R., Gore, E., Komaki, R. U., Albain, K. S., Sause, W. T., & Curran, W. J. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.09.004 · Cited by 297
Self-citation
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
Daly, M. E., Singh, N., Ismaila, N., Antonoff, M. B., Arenberg, D. A., Bradley, J., David, E., Detterbeck, F., Früh, M., Gubens, M. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02528 · Cited by 298
Therapeutic management options for stage III non-small cell lung cancer
Yoon, S. M., Shaikh, T., & Hallman, M. A. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i1.1 · Cited by 253
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
Linardou, H., Dahabreh, I. J., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.62 · Cited by 236
ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
Gerber, D. E., & Minna, J. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.033 · Cited by 220
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A., & Eckhardt, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8168 · Cited by 217
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Passaro, A., Leighl, N. B., Blackhall, F. H., Popat, S., Kerr, K. M., Ahn, M., Arcila, M. E., Arrieta, O. G., Planchard, D., de Marinis, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.003 · Cited by 209
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201
Self-citation
EGFR-mutated lung cancer: a paradigm of molecular oncology
Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010) · Oncotarget · doi:10.18632/oncotarget.186 · Cited by 197
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial
Liang, J., Bi, N., Wu, S., Chen, M., Lv, C., Zhao, L., SHI, A., Jiang, W., Xu, Y., Zhou, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx009 · Cited by 196
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
Hui, R., Özgüroğlu, M., Villegas, A. E., Daniel, D. B., Vicente, D., Murakami, S., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30519-4 · Cited by 185
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
Casal-Mouriño, A., Ruano‐Raviña, A., Lorenzo-González, M., Rodríguez-Martínez, Á., Giraldo-Osorio, A., Varela‐Lema, L., Pereiro-Brea, T., Barros-Dios, J. M., Valdés, L., & Pérez‐Ríos, M. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.40 · Cited by 178
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179
Durm, G. A., Jabbour, S. K., Althouse, S. K., Liu, Z., Sadiq, A. A., Zon, R. T., Jalal, S. I., Kloecker, G. H., Williamson, M., Reckamp, K. L., et al. (2020) · Cancer · doi:10.1002/cncr.33083 · Cited by 167
Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324
Blumenschein, G. R., Paulus, R., Curran, W. J., Robert, F., Fossella, F. V., Werner‐Wasik, M., Herbst, R. S., Doescher, P. O., Choy, H., & Komaki, R. U. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.7875 · Cited by 164
Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
Burotto, M., Manasanch, E. E., Wilkerson, J., & Fojo, T. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0154 · Cited by 158
Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial
Ready, N., Janne, P. A., Bogart, J. A., DiPetrillo, T. A., Garst, J. L., Graziano, S. L., Gu, L., Wang, X., Green, M. R., & Vokes, E. E. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181eba657 · Cited by 146
Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea
Gerber, D. E., & Schiller, J. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7459 · Cited by 141
Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials
Mouillet, G., Monnet, É., Milleron, B. J., Puyraveau, M., Quoix, É., David, P., Ducoloné, A., Molinier, O., Zalcman, G., Depierre, A., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824c7d92 · Cited by 134
SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status
Maguire, J., Khan, I., McMenemin, R. M., O'Rourke, N., McNee, S. G., Kelly, V., Peedell, C., & Snee, M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.07.009 · Cited by 133
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
Chen, G., Kronenberger, P., Teugels, E., Umelo, I. A., & Grève, J. D. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-28 · Cited by 132
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Aredo, J. V., Mambetsariev, I., Hellyer, J. A., Amini, A., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., Cabebe, E. C., Naidoo, J., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1628 · Cited by 134
Radiotherapy and immunology
Wang, L., Lynch, C. M., Pitroda, S. P., Piffkó, A., Yang, K., Huser, A. K., Liang, H. L., & Weichselbaum, R. R. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232101 · Cited by 139
Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review
Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 132
EGFR Blockade Enriches for Lung Cancer Stem–like Cells through Notch3-Dependent Signaling
Arasada, R. R., Amann, J. M., Rahman, M. A., Huppert, S. S., & Carbone, D. P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3724 · Cited by 124
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)
Gaafar, R. M., Surmont, V. F. M., Scagliotti, G. V., van Klaveren, R. J., Papamichael, D., Welch, J. J., Hasan, B., Torri, V., & van Meerbeeck, J. P. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.045 · Cited by 118
Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
Hirsch, F. R., Janne, P. A., Eberhardt, W., Cappuzzo, F., Thatcher, N., Pirker, R., Choy, H., Kim, E. S., Paz-Ares, L. G., Gandara, D. R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ed0ff · Cited by 122
Self-citation
50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer
Wakelee, H. A., Kelly, K. L., & Edelman, M. J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.177 · Cited by 114
Self-citation
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications
Derer, A., Deloch, L., Rubner, Y., Fietkau, R., Frey, B., & Gaipl, U. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00505 · Cited by 113
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials
Shi, L., Tang, J., Li, T., & Liu, Z. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.016 · Cited by 115
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
Park, K., Vansteenkiste, J., Lee, K. H., Pentheroudakis, G., Zhou, C., Prabhash, K., Seto, T., Voon, P. J., Tan, D. S. W., Yang, J. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.026 · Cited by 111
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non–Small-Cell Lung Cancer
Steuer, C. E., Behera, M., Ernani, V., Higgins, K. A., Saba, N. F., Shin, D. M., Pakkala, S., Pillai, R. N., Owonikoko, T. K., Curran, W. J., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4280 · Cited by 108
Mechanisms of tumor resistance to EGFR-targeted therapies
Hopper-Borge, E. A., Nasto, R. E., Ratushny, V., Weiner, L. M., Golemis, E. A., & Astsaturov, I. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712590902735795 · Cited by 109
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
O’Leary, C. G., Gasper, H. M., Sahin, K. B., Tang, M., Kulasinghe, A., Adams, M. N., Richard, D. J., & O'Byrne, K. J. (2020) · Pharmaceuticals · doi:10.3390/ph13100273 · Cited by 114
Targeted Therapies for Lung Cancer
Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V., & Minna, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e701a · Cited by 106
Drugs that Target Specificity Proteins Downregulate Epidermal Growth Factor Receptor in Bladder Cancer Cells
Chadalapaka, G., Jutooru, I., Burghardt, R. C., & Safe, S. H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0493 · Cited by 98
Radiation-induced amphiregulin drives tumour metastasis
Piffkó, A., Yang, K., Panda, A., Heide, J., Tesak, K., Wen, C., Zawieracz, K., Wang, L., Naccasha, E. Z., Bugno, J., et al. (2025) · Nature · doi:10.1038/s41586-025-08994-0 · Cited by 109
Surgery for NSCLC in the era of personalized medicine
Mitsudomi, T., Suda, K., & Yatabe, Y. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.22 · Cited by 98
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Arasada, R. R., Shilo, K., Yamada, T., Zhang, J., Yano, S., Ghanem, R., Wang, W., Takeuchi, S., Fukuda, K., Katakami, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05626-2 · Cited by 93
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
Gazdar, A. F. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9201-z · Cited by 99
Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
Yoshida, T., Zhang, G., & Haura, E. B. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.014 · Cited by 92
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 88
Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer
Cohen, E. E. W., Haraf, D. J., Kunnavakkam, R., Stenson, K. M., Blair, E. A., Brockstein, B., Lester, E. P., Salama, J. K., Dekker, A., Williams, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0397 · Cited by 86
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non–Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies
Stinchcombe, T. E., Zhang, Y., Vokes, E. E., Schiller, J. H., Bradley, J. D., Kelly, K. L., Curran, W. J., Schild, S. E., Movsas, B., Clamon, G. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4758 · Cited by 84
Self-citation
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
Domvri, K., Zarogoulidis, P., Darwiche, K., Browning, R. F., Jr., Li, Q., Turner, J. F., Kioumis, I. P., Spyratos, D., Porpodis, Κ., Papaiwannou, A., et al. (2013) · Journal of Cancer · doi:10.7150/jca.7734 · Cited by 82
Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy
Koh, P. K., Finn, C. F., Blackhall, F. H., & Ruysscher, D. D. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.003 · Cited by 81
Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer
Wang, L., Wu, S., Ou, G., Bi, N., Li, W., Ren, H., Cao, J., Liang, J., Li, J., Zhou, Z., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.02.011 · Cited by 80
Targeted therapies in the treatment of advanced/metastatic NSCLC
Pallis, A. G., Serfass, L., Dziadziuszko, R., van Meerbeeck, J. P., Fennell, D. A., Lacombe, D., Welch, J., & Gridelli, C. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.005 · Cited by 78
New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer
Salama, J. K., & Vokes, E. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5064 · Cited by 78
GILT—A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer
Flentje, M. P., Huber, R. M., Engel-Riedel, W., Andreas, S., Kollmeier, J., Staar, S., Dickgreber, N. J., Vaissière, N., Almeida, C. D., Edlich, B., et al. (2016) · Strahlentherapie und Onkologie · doi:10.1007/s00066-016-0941-8 · Cited by 77
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
Qi, W., Sun, Y., Shen, Z., & Yao, Y. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000189 · Cited by 76
Clinical Trials Integrating Immunotherapy and Radiation for Non–Small-Cell Lung Cancer
Daly, M. E., Monjazeb, A. M., & Kelly, K. L. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000686 · Cited by 74
Self-citation
Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer
van Baardwijk, A. A. W., Reymen, B. J. T., Wanders, S. L., Borger, J. H., Öllers, M., Dingemans, A. C., Bootsma, G. P., Geraedts, W. H., Pitz, C. C. M., Lunde, R., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.014 · Cited by 74
Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency
Hu, S., Fu, W., Li, T., Yuan, Q., Wang, F., Lv, G., Lv, Y., Fan, X., Shen, Y., Lin, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0339 · Cited by 72
Targeting cancer stem cells in the clinic: Current status and perspectives
Annett, S., & Robson, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.001 · Cited by 76
Interdisciplinary multimodality management of stage III nonsmall cell lung cancer
Huber, R. M., Ruysscher, D. D., Hoffmann, H., Reu, S., & Tufman, A. (2019) · European Respiratory Review · doi:10.1183/16000617.0024-2019 · Cited by 71
Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer
Zhang, X., Zang, J., Xu, J., Bai, C., Qin, Y., Liu, K., Wu, C., Wu, M., He, Q., Zhang, S., et al. (2011) · Chest · doi:10.1378/chest.10-2745 · Cited by 71
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
Xu, L., Xi, J., Zhong, W., Mao, W., Wu, L., Shen, Y., Liu, Y., Chen, C., Cheng, Y., Xu, L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.020 · Cited by 70
Perspectives on Treatment Advances for Stage III Locally Advanced Unresectable Non-Small-Cell Lung Cancer
Cheema, P. K., Rothenstein, J. M., Melosky, B. L., Brade, A. M., & Hirsh, V. (2019) · Current Oncology · doi:10.3747/co.25.4096 · Cited by 85
EGFR inhibition in the treatment of non‐small cell lung cancer
Gerber, D. E. (2008) · Drug Development Research · doi:10.1002/ddr.20268 · Cited by 70
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer
Komaki, R. R., Allen, P. K., Wei, X., Blumenschein, G. R., Tang, X., Lee, J. J., Welsh, J. W., Wistuba, I. I., Liu, D. D., & Hong, W. K. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.02.005 · Cited by 69
Gefitinib for advanced non-small cell lung cancer
Sim, E., Yang, I. A., Wood-Baker, R. R., Bowman, R., & Fong, K. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006847.pub2 · Cited by 71
Radiation dose effect in locally advanced non-small cell lung cancer.
Kong, F., Zhao, J., Wang, J., & Finn, C. F. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2014.01.23 · Cited by 67
A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer
Butts, C. A., Murray, R. N., Smith, C. J., Ellis, P. M., Jasas, K., Maksymiuk, A. W., Goss, G. D., Ely, G., Beier, F., & Soulières, D. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.101 · Cited by 65
New Molecular Targeted Therapies Integrated With Radiation Therapy in Lung Cancer
Provencio, M., Sánchez, A., Garrido, P., & Valcárcel, F. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.012 · Cited by 64
C-Met Inhibitor MK-8003 Radiosensitizes c-Met–Expressing Non–Small-Cell Lung Cancer Cells With Radiation-Induced c-Met–Expression
Bhardwaj, V., Zhan, Y., Cortez, M. A., Ang, K. K., Molkentine, D. P., Munshi, A., Raju, U., Komaki, R. K., Heymach, J. V., & Welsh, J. W. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318257cc89 · Cited by 63
Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development
Decoster, L., Wauters, I., & Vansteenkiste, J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr564 · Cited by 63
Gefitinib
Sanford, M., & Scott, L. J. (2009) · Drugs · doi:10.2165/10489100-000000000-00000 · Cited by 60
Epidermal Growth Factor Receptor Mutation Is Associated With Longer Local Control After Definitive Chemoradiotherapy in Patients With Stage III Nonsquamous Non–Small-Cell Lung Cancer
Yagishita, S., Horinouchi, H., Taniyama, T. K., Nakamichi, S., Kitazono, S., Mizugaki, H., Kanda, S., Fujiwara, Y., Nokihara, H., Yamamoto, N., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.08.344 · Cited by 60
Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
Oxnard, G. R., Janjigian, Y. Y., Arcila, M. E., Sima, C. S., Kass, S. L., Riely, G. J., Pao, W. J., Kris, M. G., Ladanyi, M., Azzoli, C. G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1080 · Cited by 62
Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
Chen, X., Liu, Y., Røe, O. D., Qian, Y., Guo, R., Zhu, L., Yin, Y., & Shu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059314 · Cited by 62
Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
Campo, M. J., Al-Halabi, H., Khandekar, M. J., Shaw, A. T., Sequist, L. V. D., & Willers, H. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0508 · Cited by 65
Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer
Garon, E. B., Pietras, R. J., Finn, R. S., Kamranpour, N., Pitts, S. L., Márquez‐Garbán, D. C., Desai, A. J., Dering, J., Hosmer, W., von Euw, E. M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827d525c · Cited by 61
Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis
Laccetti, A. L., Pruitt, S. L., Xuan, L., Halm, E. A., & Gerber, D. E. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.029 · Cited by 60
Systemic and Radiation Therapy Approaches for Locally Advanced Non–Small-Cell Lung Cancer
Higgins, K. A., Puri, S., & Gray, J. E. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01707 · Cited by 60
Outcomes After Combined Modality Therapy forEGFR-Mutant and Wild-Type Locally Advanced NSCLC
Mak, R. H., Doran, E., Muzikansky, A., Kang, J., Neal, J. W., Choi, N. C., Willers, H., Jackman, D. M., & Sequist, L. V. D. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0040 · Cited by 59
Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey from 1998 to 2003
Morgensztern, D., Waqar, S. N., Subramanian, J., Gao, F., Trinkaus, K. M., & Govindan, R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318267d032 · Cited by 59
Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non–Small-Cell Lung Cancer (RTOG 3505)
Gerber, D. E., Urbanic, J. J., Langer, C. J., Hu, C., Chang, I., Lü, B., Movsas, B., Jeraj, R., Curran, W. J., & Bradley, J. D. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.10.009 · Cited by 59
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54
A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer
Rodriguez, C. P., Adelstein, D. J., Rice, T. W., Rybicki, L. A., Videtic, G. M. M., Saxton, J. P., Murthy, S. C., Mason, D. P., & Ives, D. I. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c5e334 · Cited by 56
Gefitinib for the treatment of non-small-cell lung cancer
Hida, T., Ogawa, S., Park, J. C., Park, J. Y., Shimizu, J., Horio, Y., & Yoshida, K. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.1.17 · Cited by 58
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction
Adelstein, D., Rodriguez, C., Rybicki, L., Ives, D., & Rice, T. (2012) · Investigational new drugs · doi:10.1007/s10637-011-9736-z · Cited by 51

Authors: Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R.
Affiliations: Sunnybrook Health Science Centre (CA)
ORCID: Kelly, Karen
Albain, Kathy S.
Ung, Yee C.
Gandara, David R.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2450-2456
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.4824
OpenAlex: W2153865661
Cited by: 573
References: 31
Citations by year: 2026: 5 · 2025: 6 · 2024: 11 · 2023: 18 · 2022: 11 · 2021: 31 · 2020: 24 · 2019: 22 · 2018: 39 · 2017: 24 · 2016: 41 · 2015: 40 · 2014: 44 · 2013: 57 · 2012: 41
FWCI: 48.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Sanofi
National Institutes of Health (2u10ca038926-25, 5r01ca037663-18)
National Cancer Institute (CA35192, U10CA004919, CA 35176, CA-11083, CA52654, CA-45377, U10CA035261, CA35281, CA 74811, CA-35261, CA-46282, CA 20319, CA-32102, U10CA074647, CA 45450, CA35119, CA 42777, U10CA045377, CA04919, U10CA058882, U10CA074811, U10CA014028, U10CA045560, U10CA063848, U10CA035178, CA 74647, U10CA045808, CA35128, CA46368, CA46441, CA 63845, U10CA046368, CA45808, CA 45461, CA67575, U10CA035090, CA 14028, U10CA020319, U10CA086780, U10CA011083, CA-58882, CA35178, CA-45807, U10CA013612, CA 37663, U10CA035119, U10CA063850, CA35431, U10CA032102, U10CA046282, U10CA045461, U10CA052654, U10CA045450, U10CA042777, U10CA035281, CA 13612, U10CA063845, U10CA045807, U10CA063844, U10CA035431, CA-35262, U10CA035192, CA 38926, U10CA035262, CA63844, CA86780, U10CA035176, U10CA035128, CA-63850, CA-63848, CA45560, U10CA067575, CA-35090, U10CA046441)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: gefitinib, maintenance therapy, non-small cell lung cancer, stage III NSCLC, inoperable lung cancer, concurrent chemoradiotherapy, cisplatin, etoposide, thoracic radiotherapy, EGFR tyrosine kinase inhibitors, survival, toxic death
MeSH terms: Docetaxel, Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Etoposide, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Quinazolines, Remission Induction, Survival Rate, Maximum Tolerated Dose, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks